Ranked by interpretable importance, issuer history, magnitude, and accounting profile. No directional recommendation.
Capital expenditure changed -26.3% from the comparable as-filed period. The change ranks at the 14th percentile of 7 prior comparable changes. This reverses 7 consecutive comparable moves in the opposite direction.
Cash & equivalents changed -47.9% from the comparable as-filed period.
Operating income changed +3.9% from the comparable as-filed period. The change ranks at the 0th percentile of 4 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
Operating cash flow changed -11.2% from the comparable as-filed period. The change ranks at the 29th percentile of 7 prior comparable changes.
Research & development changed -14.9% from the comparable as-filed period. The change ranks at the 50th percentile of 4 prior comparable changes. This reverses 4 consecutive comparable moves in the opposite direction.
Free-cash-flow proxy changed -5.6% from the comparable as-filed period. The change ranks at the 0th percentile of 7 prior comparable changes.
Net income changed +3.2% from the comparable as-filed period. This reverses 3 consecutive comparable moves in the opposite direction.
Method Importance combines metric-family relevance, magnitude, issuer-history unusualness, persistence, and financial-statement significance. It is analytical prioritization, not a legal materiality conclusion or investment signal.